Follow The Filings

BDSX Biodesix Inc.

Health Care, filed as BIODESIX INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Sold by 1 manager in 2026 Q2

  • 1 Owner
  • Max 0.4%
  • $4.1M
  • 1 reduce

In 2026 Q2 James Silverman trimmed Biodesix.

Who owns this now

Largest portfolio weights among holders, up to 0.4% (James Silverman, Opaleye Management). Not free-float ownership.

  1. James Silverman Reduce 0.37%

Who owns BDSX

Sorted by value, long equity only, as of 2026 Q2.

History
James Silverman, Opaleye Management 0.37%, was 0.46% Reduce −24.4% 180,000 $4.1M History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by BDSX's executives, directors and 10% owners in the last 12 months, from their Form 4s

All BDSX insider trades
  • $3.1M bought by 1 insider
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Jack W Schuler 10% owner
    Buy
    $367K 15,000 shares at $24.47 +2.8% to stake
    Traded Aug 12 Filed Aug 13
    ↗
  2. Jack W Schuler 10% owner
    Buy
    $666K 27,600 shares at $24.13 +5.4% to stake
    Traded Aug 10–11 Filed Aug 12
    ↗
  3. Jack W Schuler 10% owner
    Buy
    $1.2M 100,000 shares at $11.81 +6.8% to stake
    Traded Jan 23–26 Filed Jan 27
    ↗
  4. Jack W Schuler 10% owner
    Buy
    $904K 82,465 shares at $10.96 +6% to stake
    Traded Jan 22 Filed Jan 26
    ↗

Also filed in the last 12 months, not counted as buying or selling: 24 option exercises and 20 sales to cover taxes.

SEC filings

Recent issuer filings from EDGAR, 18 shown.

Filed Form Detail Links
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G — Filing Doc
424B3 Filing Doc
8-K 5.07,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G — Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
8-K 2.02,9.01 Filing Doc
10-K Filing Doc
SCHEDULE 13D/A — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc

Source: SEC EDGAR submissions, updated 15 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $49.09M $71.32M $88.5M
Net income -$52.15M -$42.93M -$35.26M
Net margin * -106.2% -60.2% -39.8%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $39.68M $39.48M $32.52M
Total non-current assets $59.41M $57.76M $54.96M
Total assets $99.1M $97.24M $87.48M
Total current liabilities $33.42M $14.32M $17.44M
Total non-current liabilities $61.1M $62.05M $72.5M
Total equity $4.58M $20.88M -$2.46M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$22.87M -$48.65M -$23.27M
Cash from investing -$23.06M -$3.44M -$0.403M
Cash from financing $29.13M $52.05M $16.42M
Net change in cash -$16.8M -$0.039M -$7.26M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.